Rus En Es
Main / ГЕРОФАРМ получил в Узбекистане регистрационное удостоверение на инсулины РинГлар и РинЛиз

GEROPHARM Obtained Marketing Authorisation for RinGlar and RinLis Insulins in Uzbekistan

2 August 2022

GEROPHARM obtained the marketing authorisation for insulin analogue biosimilars glargine and lispro from the Ministry of Health of the Republic of Uzbekistan.

Thus, Uzbekistan became the third country where GEROPHARM obtained the marketing authorisation for RinLis, and the fourth one where RinGlar is registered.
Plans are underway to localise insulin production at Zuma Pharma site, the Uzbek company, next year. GEROFARM will transfer the production technology for insulin biosimilars such as glargine, lispro, and biphasic lispro in pen injectors and cartridges to the partner. This agreement was signed during Saint Petersburg International Economic Forum (SPIEF).

You are a health care professional?

Go up